PHARMACYTE BIOTECH INC's ticker is PMCBD and the CUSIP is 71715X203. A total of 32 filers reported holding PHARMACYTE BIOTECH INC in Q4 2022. The put-call ratio across all filers is 1.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $542,810 | +23.1% | 258,481 | +67.6% | 0.11% | +12.9% |
| Q2 2023 | $441,104 | -78.6% | 154,232 | -78.7% | 0.10% | -64.4% |
| Q1 2023 | $2,062,624 | -3.8% | 723,271 | -1.2% | 0.28% | -12.9% |
| Q4 2022 | $2,145,068 | +46.2% | 732,105 | +19.8% | 0.33% | +94.0% |
| Q3 2022 | $1,467,000 | +619.1% | 611,163 | +570.9% | 0.17% | +630.4% |
| Q2 2022 | $204,000 | – | 91,095 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 1,061,411 | $2,378,000 | 1.62% |
| Ayrton Capital LLC | 153,130 | $343,000 | 0.56% |
| Shay Capital LLC | 982,698 | $2,201,000 | 0.44% |
| EQUITEC PROPRIETARY MARKETS, LLC | 342,994 | $768,000 | 0.22% |
| FNY Investment Advisers, LLC | 15,290 | $34,000 | 0.02% |
| K2 PRINCIPAL FUND, L.P. | 91,095 | $204,000 | 0.02% |
| Schonfeld Strategic Advisors LLC | 26,200 | $59,000 | 0.00% |
| Aspire Private Capital, LLC | 800 | $2,000 | 0.00% |
| OSAIC HOLDINGS, INC. | 1,758 | $3,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 1,734 | $4,000 | 0.00% |